Journal
MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 15, Issue 9, Pages 731-750Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557515666150521162237
Keywords
Histone Deacetylase; cancer; isoform; Romidepsin; US-FDA
Categories
Funding
- Council of Scientific and Industrial Research
- University Grant Commission
Ask authors/readers for more resources
Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has summarized the inhibitors, based on their specificity towards different isoforms within this class. Further various recent United State (US) patents and the HDAC inhibitors, used singly or in combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available